Cucurbitacin B, a naturally occurring triterpene analog and a potential cancer chemotherapeutic agent, could repress cancer cell progression.

Pyrintegrin, a β1-integrin agonist, is a potent and cell-permeable promoter of the adhesion of individually dissociated hESCs on matrigel- or laminin-, but not gelatin-coated surfaces, substantially reducing trypsinization-induced apoptosis.

Tirofiban hydrochloride (also known as L700462 or MK383) is a novel non-peptide antagonist of glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) that is used as an antiplatelet drug.

Cilengitide (also known as EMD 121974, NSC 707544) is a highly potent integrin inhibitor for the αvβ3 receptor and the αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; it showed ~10-fold selectivity against gpIIbIIIa.

CWHM-12 is a novel potent small molecule inhibitor of αV integrins with IC50s of 1.8/0.8/1.5/0.2 nM for αvβ1/αvβ3/αvβ8.

QLT0267 (ILK-IN-3) is a novel, potent, selective ATP-competitive inhibitor of integrin-linked kinase (ILK) with potential anticancer activity.

ATN-161 is a novel and potent small peptide inhibitor of the integrin α5β1, it inhibits the angiogenesis and growth of liver metastases in a murine model.

Cilengitide TFA (also known as EMD 121974; NSC-707544; EMD-85189; D-03497), the trifluoroacetic acid salt of cilengitide, is a highly potent and selective integrin inhibitor for the αvβ3 receptor and the αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; it showed ~10-fold selectivity against gpIIbIIIa.

ATN-161 TFA, the trifluoroacetic acid salt of ATN161, is a novel and potent small peptide inhibitor of the integrin α5β1 with potential anticancer activity.

MK-0429 is a compound that was originally developed as a selective and potent αvβ3 inhibitor for the treatment of osteoporosis, on renal function and fibrosis.